Inovalon (INOV) Earns Daily News Impact Score of -0.03

Media headlines about Inovalon (NASDAQ:INOV) have been trending somewhat negative recently, according to Accern. Accern identifies positive and negative press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Inovalon earned a coverage optimism score of -0.03 on Accern’s scale. Accern also gave media coverage about the technology company an impact score of 46.0643360398298 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Inovalon (NASDAQ INOV) opened at $10.45 on Monday. The company has a market capitalization of $1,509.00, a P/E ratio of 43.54, a PEG ratio of 2.99 and a beta of 0.96. The company has a debt-to-equity ratio of 0.32, a current ratio of 4.82 and a quick ratio of 4.82. Inovalon has a 12-month low of $10.32 and a 12-month high of $17.80.

How to Become a New Pot Stock Millionaire

Inovalon (NASDAQ:INOV) last issued its earnings results on Tuesday, February 20th. The technology company reported $0.06 EPS for the quarter, missing the consensus estimate of $0.07 by ($0.01). The firm had revenue of $114.60 million during the quarter, compared to analyst estimates of $116.83 million. Inovalon had a return on equity of 4.79% and a net margin of 7.51%. Inovalon’s revenue was up 19.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.05 EPS. research analysts expect that Inovalon will post 0.25 earnings per share for the current year.

A number of equities research analysts have weighed in on the company. ValuEngine lowered Inovalon from a “hold” rating to a “sell” rating in a research note on Wednesday, March 14th. Wells Fargo restated a “market perform” rating and set a $14.00 price objective (down previously from $16.00) on shares of Inovalon in a research note on Wednesday, February 21st. BidaskClub lowered Inovalon from a “sell” rating to a “strong sell” rating in a research note on Thursday, December 14th. TheStreet upgraded Inovalon from a “d+” rating to a “c” rating in a research note on Thursday, March 15th. Finally, Morgan Stanley lowered Inovalon from an “equal weight” rating to an “underweight” rating and set a $10.00 price objective for the company. in a research note on Wednesday, March 14th. Three research analysts have rated the stock with a sell rating and four have issued a hold rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $12.00.

In other news, insider Shauna L. Vernal sold 44,270 shares of Inovalon stock in a transaction that occurred on Tuesday, January 23rd. The stock was sold at an average price of $14.00, for a total value of $619,780.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 48.28% of the stock is currently owned by company insiders.

TRADEMARK VIOLATION NOTICE: “Inovalon (INOV) Earns Daily News Impact Score of -0.03” was originally posted by Ticker Report and is the sole property of of Ticker Report. If you are accessing this article on another website, it was copied illegally and republished in violation of US and international copyright and trademark laws. The legal version of this article can be viewed at https://www.tickerreport.com/banking-finance/3301539/inovalon-inov-earns-daily-news-impact-score-of-0-03.html.

Inovalon Company Profile

Inovalon Holdings, Inc (Inovalon) is a technology company. The Company provides cloud-based platforms empowering a data-driven transformation from volume-based to value-based models to the healthcare industry. Leveraging large-scale data interconnectivity capabilities, unparalleled proprietary data sets, advanced analytics, data-driven intervention systems, and subject matter expertise, Inovalon enables the assessment and improvement of clinical and quality outcomes and financial performance across the healthcare ecosystem.

Insider Buying and Selling by Quarter for Inovalon (NASDAQ:INOV)

Receive News & Ratings for Inovalon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovalon and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Juno Therapeutics Inc  Receives $57.93 Average Target Price from Brokerages
Juno Therapeutics Inc Receives $57.93 Average Target Price from Brokerages
Lexicon Pharmaceuticals  Receives $25.67 Average Target Price from Analysts
Lexicon Pharmaceuticals Receives $25.67 Average Target Price from Analysts
PMC Commercial Trust  Earns Daily News Sentiment Rating of 0.27
PMC Commercial Trust Earns Daily News Sentiment Rating of 0.27
WideOpenWest  Earning Somewhat Favorable News Coverage, Analysis Finds
WideOpenWest Earning Somewhat Favorable News Coverage, Analysis Finds
Brokerages Set RingCentral  Target Price at $53.92
Brokerages Set RingCentral Target Price at $53.92
Comparing Kingstone Companies  & Its Competitors
Comparing Kingstone Companies & Its Competitors


© 2006-2018 Ticker Report. Google+.